C12N5/0735

Media and methods for enhancing the survival and proliferation of stem cells

The present disclosure relates to improved supplements, culture media and methods for enhancing the survival or proliferation of mammalian stem cells. In particular, adding a lipid supplement, such as a lipid-enriched carrier (e.g. a lipid-enriched albumin), to the culture medium may enhance the survival and/or proliferation of the stem cells by at least 5% to 65% as compared to a culture medium that does not contain the lipid supplement.

Device and method for monitoring the temperature of a cryopreserved biological sample

The invention relates to a method for monitoring the temperature of a cryopreserved biological sample. The invention also relates to a device for monitoring the temperature of a cryopreserved biological sample. The device (10) for monitoring the temperature of a cryopreserved biological sample comprises a sample container (1) having a receiving space (2) for receiving a biological sample (6). The device also comprises at least one chamber (11) having an interior that is not fluidically connected to the receiving space (2) and is only partially filled with an indicator substance (7) with a melting temperature in a region of −20° C. to −140° C. The chamber (11) has a barrier (13) that causes the indicator substance (7) to move into a second sub-region (12b) of the chamber (11) when the indicator substance (7) in a first sub-region (12a) of the chamber is in the fluid aggregate state.

Methods of treating neuropsychiatric disorders

The present disclosure is directed to a method of treating a neuropsychiatric disorder. This method involves selecting a subject having the neuropsychiatric disorder and administering to the selected subject a preparation of glial progenitor cells at a dosage effective to treat the neuropsychiatric disorder in the subject. Another aspect of the disclosure is directed to a method of treating a neuropsychiatric disorder that includes selecting a subject having the neuropsychiatric disorder and administering, to the selected subject, a potassium (K.sup.+) channel activator at a dosage effective to restore normal brain interstitial glial K.sup.+ levels in the selected subject and treat the neuropsychiatric disorder is also disclosed.

STEM CELL FATE ENGINEERING METHODS
20230002728 · 2023-01-05 ·

This disclosure relates generally to the differentiation of human pluripotent stem cells, and more particularly to a method of spatially adsorbing morphogens to differentiate human pluripotent stem cells.

PERICYTE CELL EXOSOMES
20220401494 · 2022-12-22 ·

Compositions and methods of use pertaining to exosomes, and more particularly to exosomes from pericytes and endothelial progenitor cells are presented.

METHODS FOR PRODUCING NEURAL CELLS
20220403331 · 2022-12-22 ·

The present invention provides differentiated neural cells and methods for making differentiated neural cells from pluripotent stem cells (PSC) at an industrial scale sufficient for high-throughput assays. The methods of the invention allow billions of PSCs and/or neural cells differentiated from the PSCs to be cryopreserved and expanded at multiple steps.

METHOD FOR PRODUCING PLURIPOTENT STEM CELL CAPABLE OF DIFFERENTIATING INTO SPECIFIC CELL AND APPLICATION THEREOF

An object of the present invention is to provide a method of producing a pluripotent stem cell capable of differentiating into a specific cell. According to the present invention, there is provided a method for producing a pluripotent stem cell capable of differentiating into a specific cell, the method including (i) a step of measuring, in a pluripotent stem cell as a sample, a phenotype associated with induction of epithelial-mesenchymal transition before differentiation induction; and (ii) a step of acquiring a pluripotent stem cell capable of differentiating into a specific cell using the measured phenotype as an indicator. According to the present invention, there are further provided a method of selecting a pluripotent stem cell capable of differentiating into a specific cell; a pluripotent stem cell capable of differentiating into a specific cell; a production method of a differentiated cell; a differentiated cell; and a method for quality evaluation of a pluripotent stem cell.

COMPOSITION FOR PROMOTING PROLIFERATION OF STEM CELLS, CONTAINING, AS ACTIVE INGREDIENT, CP1P OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

The present invention relates to: a composition for promoting the proliferation of pluripotent stem cells, containing, as an active ingredient, cP1P or a pharmaceutically acceptable salt thereof; and a composition added to a stem cell culture liquid. When culturing stem cells by using a composition for promoting the proliferation of stem cells and a composition added to a stem cell culture medium, according to the present invention, sternness can be strengthened, growth can be promoted, and apoptosis can be inhibited.

Media for culturing stem cells

Well-defined, xeno-free culture media which comprise a TGF-beta isoform or the chimera formed between IL6 and the soluble IL6 receptor (IL6RIL6), which are capable of maintaining stem cells, and particularly, human embryonic stem cells, in an undifferentiated state are provided. Also provided are cell cultures comprising the culture media and the stem cells and methods of expanding and deriving embryonic stem cells in such well-defined, xeno-free culture media. In addition, the present invention provides methods of differentiating ESCs or EBs formed therefrom for the generation of lineage specific cells.

AMELIORATION AND TREATMENT OF BRAIN DISORDER RESULTING FROM FETAL GROWTH RETARDATION USING PLURIPOTENT STEM CELLS

The purpose of the present invention is to provide a novel medical application of pluripotent stem cells (muse cells) in regeneration medicine. The present invention provides a cell preparation and a pharmaceutical composition which are for amelioration and treatment of brain disorders resulting from fetal growth retardation, such as abnormal motor quality or abnormal neurological development, and which contain SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue from a live body or cultured mesenchymal cells. It is assumed that this cell preparation is based on a mechanism where muse cells that are administered to objects having the disorders are engrafted on an impaired brain tissue, thereby ameliorating or treating the disorders.